RxDoctor Payments Data

Karen Hanna, MD

Cardiovascular Disease · Savannah, GANPI 1316910862

Payments from drug & device makers

$3,880in general payments, 2019–2025

Across 238 payments — averaging $16.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$704
  • Amgen$661
  • Novartis$391
  • E.r. Squibb & Sons, L.L.C.$331
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$289
  • Cvrx, Inc.$245
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$3,875100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,880 in reported general payments places this provider in the 55th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$223,039
Medicare patients
1,023
Services billed
3,422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban901$780,446
EntrestoSacubitril/Valsartan348$318,903
XareltoRivaroxaban330$267,076
Repatha SureclickEvolocumab98$81,534
JardianceEmpagliflozin53$41,308
FarxigaDapagliflozin Propanediol20$22,380
Metoprolol Succinate1,244$12,342
Praluent PenAlirocumab20$9,722
Propafenone Hcl ErPropafenone Hcl22$8,017
Ranolazine ErRanolazine62$6,167
Flecainide Acetate159$4,395
Losartan Potassium392$2,930
Atorvastatin Calcium285$2,760
Amiodarone Hcl166$2,758
SotalolSotalol Hcl179$2,673

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$171$780,446901 claims
NovartisEntresto$391$318,903348 claims
Johnson & JohnsonXarelto$704$267,076330 claims
Boehringer IngelheimJardiance$169$41,30853 claims
AstraZenecaFarxiga$42$22,38020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →